Maurizio Marvisi1, Francesco Ferrozzi2, Laura Balzarini3, Chiara Mancini3, Sara Ramponi3, Mario Uccelli2. 1. Dept. of Internal Medicine and Pneumology, Istituto Figlie di San Camillo, Cremona, Italy. Electronic address: mmarvis@alice.it. 2. Dept. of Radiology, Istituto Figlie di San Camillo, Cremona, Italy. 3. Dept. of Internal Medicine and Pneumology, Istituto Figlie di San Camillo, Cremona, Italy.
Abstract
BACKGROUND: At the end of February, the Lombardy region (Northern Italy) was involved in the pandemic spread of the new COVID-19. We here summarize the clinical and radiological characteristics of 90 confirmed cases and analyze their role in predicting the evolution of fibrosis. METHODS: We retrospectively analyzed the clinical and radiological data of 90 patients with COVID-19 pneumonitis. All subjects underwent an HRCT study on the day of admission and eight weeks later, and were treated with lopinavir + ritonavir (Kaletra) 400/100 mg two times a day or darunavir + ritonavir two times a day, and Hydroxychloroquine 200 mg two times a day. Pulmonary fibrosis was defined according to the Fleischner Society glossary of terms for thoracic imaging. RESULTS: Twenty-three patients developed pulmonary fibrosis (25.5%): 15 were males, whose mean age was 75 ± 15. The majority were active smokers (60.8%) and had comorbidities (78.2%), above all, hypertension (47.8%), and diabetes (34.7%). Interestingly, in our series of cases, the "reversed halo sign" is frequent (63%) and seems to be a typical COVID-19 pneumonitis pattern. The patients showing fibrosis had a higher grade of systemic inflammation (ESR and PCR) and appeared to have bone marrow inhibition with a significant reduction in platelets, leukocytes, and hemoglobin. CONCLUSIONS: To conclude, our data showed that the reversed halo sign associated with a ground-glass pattern may be a typical HRCT pattern of COVID-19 pneumonitis. The evolution to pulmonary fibrosis is frequent in older males and patients with comorbidities and bone marrow involvement.
BACKGROUND: At the end of February, the Lombardy region (Northern Italy) was involved in the pandemic spread of the new COVID-19. We here summarize the clinical and radiological characteristics of 90 confirmed cases and analyze their role in predicting the evolution of fibrosis. METHODS: We retrospectively analyzed the clinical and radiological data of 90 patients with COVID-19 pneumonitis. All subjects underwent an HRCT study on the day of admission and eight weeks later, and were treated with lopinavir + ritonavir (Kaletra) 400/100 mg two times a day or darunavir + ritonavir two times a day, and Hydroxychloroquine 200 mg two times a day. Pulmonary fibrosis was defined according to the Fleischner Society glossary of terms for thoracic imaging. RESULTS: Twenty-three patients developed pulmonary fibrosis (25.5%): 15 were males, whose mean age was 75 ± 15. The majority were active smokers (60.8%) and had comorbidities (78.2%), above all, hypertension (47.8%), and diabetes (34.7%). Interestingly, in our series of cases, the "reversed halo sign" is frequent (63%) and seems to be a typical COVID-19 pneumonitis pattern. The patients showing fibrosis had a higher grade of systemic inflammation (ESR and PCR) and appeared to have bone marrow inhibition with a significant reduction in platelets, leukocytes, and hemoglobin. CONCLUSIONS: To conclude, our data showed that the reversed halo sign associated with a ground-glass pattern may be a typical HRCT pattern of COVID-19 pneumonitis. The evolution to pulmonary fibrosis is frequent in older males and patients with comorbidities and bone marrow involvement.
Authors: Emanuele Pontali; Denise Rossato Silva; Florian M Marx; Jose Antonio Caminero; Rosella Centis; Lia D'Ambrosio; Jose Maria Garcia-Garcia; Jeremiah Chakaya Muhwa; Simon Tiberi; Giovanni Battista Migliori Journal: Arch Bronconeumol Date: 2022-06-10 Impact factor: 6.333
Authors: Christopher C Huntley; Ketan Patel; Shahnoor-E-Salam Bil Bushra; Farah Mobeen; Michael N Armitage; Anita Pye; Chloe B Knight; Alyaa Mostafa; Marie Kershaw; Aishah Z Mughal; Emily McKemey; Alice M Turner; P Sherwood Burge; Gareth I Walters Journal: ERJ Open Res Date: 2022-05-30
Authors: Bnar J Hama Amin; Fahmi H Kakamad; Gasha S Ahmed; Shaho F Ahmed; Berwn A Abdulla; Shvan H Mohammed; Tomas M Mikael; Rawezh Q Salih; Razhan K Ali; Abdulwahid M Salh; Dahat A Hussein Journal: Ann Med Surg (Lond) Date: 2022-04-06
Authors: Merel E Hellemons; Susanne Huijts; L Martine Bek; Julia C Berentschot; Gizal Nakshbandi; Carin A M Schurink; Johan H Vlake; Michel E van Genderen; Jasper van Bommel; Diederik Gommers; Arlette Odink; Pierluigi Ciet; Marc C Shamier; Corine Geurts van Kessel; Sara J Baart; Gerard M Ribbers; Rita J G van den Berg-Emons; Majanka H Heijenbrok-Kal; Joachim G J V Aerts Journal: Ann Am Thorac Soc Date: 2022-04